GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,485.60p
   
  • Change Today:
      24.60p
  • 52 Week High: 2,263.00p
  • 52 Week Low: 1,296.00p
  • Currency: UK Pounds
  • Shares Issued: 4,094.68m
  • Volume: 7,774,368
  • Market Cap: £60,831m
  • RiskGrade: 129

Latest ShareCast News

FDA approves GSK anaemia drug

By Abigail Townsend

Date: Thursday 02 Feb 2023

(Sharecast News) - The US regulator has given the green light to a GSK treatment for anaemia in patients with chronic kidney disease, the medicines and vaccines group confirmed on Thursday.

GSK Regulatory News

Daprodustat approved by US FDA for anaemia of CKD 02-Feb-2023 07:00 RNS
Director/PDMR Shareholding 01-Feb-2023 15:30 RNS
Total Voting Rights 01-Feb-2023 15:00 RNS
Benlysta granted Orphan Drug Designation by US FDA 01-Feb-2023 07:05 RNS
Final Results 01-Feb-2023 07:00 RNS

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,485.60p
Change Today 24.60p
% Change 1.68 %
52 Week High 2,263.00p
52 Week Low 1,296.00p
Volume 7,774,368
Shares Issued 4,094.68m
Market Cap £60,831m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
58.29% below the market average58.29% below the market average58.29% below the market average58.29% below the market average58.29% below the market average
82.76% above the sector average82.76% above the sector average82.76% above the sector average82.76% above the sector average82.76% above the sector average
Price Trend
40.31% below the market average40.31% below the market average40.31% below the market average40.31% below the market average40.31% below the market average
25.81% above the sector average25.81% above the sector average25.81% above the sector average25.81% above the sector average25.81% above the sector average
Income
67.69% above the market average67.69% above the market average67.69% above the market average67.69% above the market average67.69% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
51.89% below the market average51.89% below the market average51.89% below the market average51.89% below the market average51.89% below the market average
75% below the sector average75% below the sector average75% below the sector average75% below the sector average75% below the sector average

What The Brokers Say

Strong Buy 2
Buy 6
Neutral 14
Sell 1
Strong Sell 2
Total 25
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q4 Q3
Ex-Div 23-Feb-23 17-Nov-22
Paid 13-Apr-23 12-Jan-23
Amount 13.75p 13.75p

Trades for 07-Feb-2023

Time Volume / Share Price
16:45 153 @ 1,485.40p
16:45 153 @ 1,485.40p
16:45 6,466 @ 1,485.40p
16:45 6,466 @ 1,485.40p
16:35 1,000 @ 1,485.60p

GSK Key Personnel

CEO Emma Walmsley
CFO Iain Mackay

Top of Page